Search results
-
Joyo starts its first pivotal trial
… x CD8 fusion protein, in relapsed cervical cancer. At ASCO 2025 the company reported two partial responses in this …
- 09/25/2025 - 12:14 -
J&J goes straight into phase 3 in prostate
… T-cell engager, possibly because phase 1 data presented at ASCO 2025 suggested that pasritamig could offer a safer … or chemo Pasritamig, uncontrolled Data presented at ASCO 2025 Source: OncologyPipeline & …
- 09/16/2025 - 14:56 -
World Lung 2025 – Ideaya challenges Zai Lab
… ph1 Presentation venue World Lung 2025 ASCO 2025 ORR* 72% (52/72)** 51% (38/74)^ …
- 09/09/2025 - 10:02 -
Novocure’s Lunar eclipse
… + Abraxane, vs gemcitabine + Abraxane Data at ASCO 2025: OS 16.2mth vs 14.2mths; filed with FDA Aug 2025, …
- 02/12/2026 - 10:42 -
BioNTech quietly drops Claudin6 work
… Ph1/2 in solid tumours Disappointing results at ASCO 2025 BNT315 (GEN1055)* Ox40 agonist Hexabody …
- 08/12/2025 - 10:34 -
No starring role for GSK’s Tim-3
… + LB4330 (anti-Claudin18.2/CD8 fusion protein); ORR 50% at ASCO 2025 BC3402 Tim-3 MAb BioCity Biopharma …
- 07/31/2025 - 14:15 -
Sino takes out the rest of Merck’s partner
… (LM-108) Anti-CCR8 MAb Pooled ph1/2 data at ASCO 2025: 18% ORR (13/74) in pancreatic cancer + anti-PD-1; …
- 07/18/2025 - 13:28 -
AbbVie steps up for Glenmark's multispecific
… T-cell engager Global ph1 Trignite-1 ; data at ASCO 2025 Unnamed Cellyan Therapeutics …
- 07/14/2025 - 10:23 -
BeOne tries to repeat the inhibitor-degrader double
… BG-68501 showed 6% uORR in 37 solid tumour patients at ASCO 2025 BG-75202 KAT6A/B inhibitor Starting …
- 07/02/2025 - 10:21 -
Exelixis claims a next-generation colorectal win
… Monotx & combos Safety, ORR, PFS, OS Data at ASCO 2025 in 1st-line renal: ORR 63% with zanza + Opdivo …
- 06/24/2025 - 16:17
